Search

Your search keyword '"VILLALOBOS-VALENCIA, RICARDO"' showing total 23 results
Start Over Author "VILLALOBOS-VALENCIA, RICARDO"
23 results on '"VILLALOBOS-VALENCIA, RICARDO"'

1. First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Author

Marth, Christian, Moore, Richard G., Bidziński, Mariusz, Pignata, Sandro, Ayhan, Ali, Rubio, M. Jesús, Beiner, Mario, Hall, Marcia, Vulsteke, Christof, Braicu, Elena Ioana, Sonoda, Kenzo, Wu, Xiaohua, Frentzas, Sophia, Mattar, André, Lheureux, Stephanie, Chen, Xiaojun, Hasegawa, Kosei, Magallanes-Maciel, Manuel, Choi, Chel Hun, Shalkova, Mariia, Kaen, Diego, Wang, Peng-Hui, Berger, Regina, Okpara, Chinyere E., McKenzie, Jodi, Yao, Lili, Orlowski, Robert, Khemka, Vivek, Gilbert, Lucy, Makker, Vicky, Kaen, Diego Lucas, Gomez Abuin, Gonzalo, Zamora, Liliana Beatriz, Alfie, Margarita Sonia, Casarini, Ignacio Alfredo, Harrison, Michelle, Ananda, Sumitra, Shannon, Catherine Margaret, Frentzas, Sophia, Friedlander, Michael, Meniawy, Tarek, Gao, Bo, Baron-Hay, Sally, Diakos, Connie, Marth, Christian, Polterauer, Stephan, Petru, Edgar, De Bock, Marlies, Vulsteke, Christof, Baurain, Jean-Francois, Van Gorp, Toon, Altintas, Sevilay, Lima, Joao Paulo da Silveira Nogueira, Mattar, Andre, de Freitas Junior, Ruffo, Santana, Rosane O., de Melo, Andreia Cristina, Franke, Fabio Andre, Zibetti Dal Molin, Graziela, Damian, Fernanda Bronzon, Guedes, João Daniel Cardoso, Ellard, Susan, Tinker, Anna, Samouëlian, Vanessa, Fortin, Suzanne, Bessette, Paul, Kolinsky, Michael, Kumar Tyagi, Nidhi, Ethier, Josee-Lyne, Gilbert, Lucy, Lheureux, Stephanie, MacKay, Helen, Lim, Charles, Wu, Xiaohua, Pan, Lingya, An, Ruifang, Chen, Xiaojun, Zheng, Hong, Wu, Yumei, Zhu, Jianqing, Yao, Shuzhong, Jia, Xuemei, Huang, Yi, Lv, Weiguo, Zhang, Yu, Zhou, Qi, Ma, Cailing, Chekerov, Radoslav, Mach, Pawel, Witteler, Ralf, Marmè, Frederik, Cadoo, Karen, Korach, Jacob, Levy, Talia, Beiner, Mario, Amnon, Amit, Scollo, Paolo, Naglieri, Emanuele, Pignata, Sandro, Zamagni, Claudio, Salutari, Vanda, Usami, Tomoka, Nakamura, Kazuto, Matsumoto, Koji, Yamagami, Wataru, Kobayashi, Yoichi, Takano, Masashi, Kato, Hidenori, Sonoda, Kenzo, Kikuchi, Akira, Katsumata, Noriyuki, Kamiura, Shoji, Horie, Koji, Hasegawa, Kosei, Tsunoda, Takuya, Suzuki, Nao, Yunokawa, Mayu, Nishio, Shin, Kudaka, Wataru, Guerrero Cabrera, Fernando Felix, Gonzalez Mendoza, Rene Lazaro, Magallanes Maciel, Manuel Ernesto, Villalobos Valencia, Ricardo, Escobar Penagos, Jose, Lopez Chuken, Yamil Alonso, Mackowiak-Matejczyk, Beata, Tarnawski, Rafal, Kalinka, Ewa, Bidzinski, Mariusz, Bednarek, Wieslawa, Danska-Bidzinska, Anna, Koralewski, Piotr, Roszak, Andrzej, Kedrova, Anna, Musaeva, Natalia, Urmancheeva, Adiliya Fettekhovna, Vasiliev, Aleksandr Gennadievich, Safina, Sufia Zievna, Lisyanskaya, Alla Sergeevna, Rykov, Ivan V., Rumyantsev, Alexey Alexandrovich, Belonogov, Aleksandr, Makarycheva, Yulia, Kim, Yong Man, Choi, Chel Hun, Kim, Yong Beom, Kim, Hee Seung, Kim, Sang Wun, Quindos Varela, Maria, Casado Herraez, Antonio, Diaz Redondo, Tamara, Rubio Perez, Maria Jesus, Romeo Marin, Margarita, Romero Noguera, Ignacio, Taus Garcia, Alvaro, Lin, Wu-Chou, Chou, Hung-Hsueh, Cheng, Wen-Fang, Lu, Chien-Hsing, Wang, Peng-Hui, Simsek, Tayup, Kose, Fatih, Ayhan, Ali, Vardar, Mehmet Ali, Ozerkan, Kemal, Hughes, Andrew, Stillie, Alison, Eminowicz, Gemma, Khalique, Saira, Shalkova, Mariia, Sukhina, Olena, Piatnytska, Tetiana, Averina, Hanna, Kulyaba, Yaroslav, Kryzhanivska, Anna, Bondarenko, Igor, Svintsitsky, Valentyn, Krasnohrud, Yuliia, Voitko, Nataliia, Buscema, Joseph, Ghamande, Sharad, Lewin, Sharyn, Graham, Deena M., Makker, Vicky, Bell, Maria, Santin, Alessandro, Lee, Christine, Blank, Stephanie, Konecny, Gottfried E., Corr, Bradley, Van Le, Linda, Moore, Richard G., Scalici, Jennifer, Anderson, Charles, Braly, Patricia, Fehniger, Julia, Westhoff, Gina, and Bollinger, Lauren

Published
2024
Full Text
View/download PDF

2. The Effects of Nebivolol-Gefitinib-Loratadine Against Lung Cancer Cell Lines.

Author

MARTÍNEZ-LIRA, JOSÉ LUIS, HERNÁNDEZ-GALLEGOS, ELISABETH, DE GUADALUPE CHÁVEZ-LÓPEZ, MARÍA, VILLALOBOS-VALENCIA, RICARDO, and CAMACHO, JAVIER

Subjects
ADRENERGIC beta blockers, NON-small-cell lung carcinoma, ALTERNATIVE treatment for cancer, DRUG repositioning, PROTEIN-tyrosine kinase inhibitors, GEFITINIB
Abstract

Background/Aim: Non-small-cell lung cancer (NSCLC) is the most frequently diagnosed malignancy and the first cause of cancer-related death. Thus, finding alternative therapeutic options is crucial. Drug repurposing offers therapeutic options in a simplified and affordable manner, especially to cancer patients in developing countries. Several drugs including antihistamines and beta-adrenergic receptor blockers (beta-blockers) display antiproliferative properties on cancer cells. Interestingly, NSCLC patients who had used either antihistamines or beta-blockers showed improved response to chemotherapy or reduced mortality in comparison to non-users of any of these drugs. However, combination therapy is gaining substantial interest in many cancers including non-EGFR mutated NSCLC. Here, we investigated the antineoplastic effect of the combination of the antihistamine loratadine, the beta-blocker nebivolol, and the tyrosine-kinase inhibitor gefitinib on NSCLC cell lines. Materials and Methods: A-549 and NCI-H1975 cell lines were used. The effect of nebivolol, gefitinib, and loratadine on the metabolic activity was studied using the MTT assay. The inhibitory concentrations (IC20 and IC50) were calculated and used in the drug-combination experiments. Apoptosis was investigated using flow cytometry; and cell survival using the colony formation assay. Results: The combination nebivolol-loratadine-gefitinib produced a significant synergistic effect on inhibiting the metabolic activity and colony formation, as well as on promoting apoptosis in both cell lines. Noteworthy, the effect on the cell line carrying the EGFR mutation (NCI-H1975) was very similar to the cell line that does not exhibit such mutation (A-549 cells). Conclusion: The nebivolol-gefitinib-loratadine combination may be a promising alternative for lung cancer treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Advanced, recurrent, and persistent cervical cancer management: in the era of immunotherapy.

Author

Galicia-Carmona, Tatiana, Alexandro Arango-Bravo, Eder, Coronel-Martínez, Jaime A., Cetina-Pérez, Lucely, Vanoye-Carlo, Elva G., Villalobos-Valencia, Ricardo, García-Pacheco, José A., and Cortés-Esteban, Patricia

Subjects
IMMUNE checkpoint inhibitors, CERVICAL cancer, OVERALL survival, CANCER treatment, COMBINATION drug therapy
Abstract

Cervical cancer constitutes a significant health burden for women worldwide despite being preventable by vaccination and screening. Advanced stages of the disease are associated with a poor prognosis, and treatment approaches have seen little change over several decades, resulting in an overall survival rate of no more than 17 months. Additionally, there are limited options for second-line treatment. The urgent need for innovative and effective therapies to improve the outlook for this group of patients, along with an enhanced understanding of the interactions between the disease and the host's immune system, has propelled immunotherapy into a rapidly advancing field with notable achievements. Among various immunotherapeutic approaches, immune checkpoint inhibitors emerge as the most advanced treatment option. Clinical trials assessing these inhibitors as single agents or in combination with chemotherapy show promising results. As immunotherapy begins to redefine standards of care for metastatic, recurrent, or persistent cervical cancer, this review addresses recent advances and current recommendations for its management in both first and second-line treatment. The goal is to provide insights into the evolving landscape of cervical cancer treatment, specifically focusing on immunotherapeutic interventions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Luft, Alexander V., Karaseva, Nina A., Kowalyszyn, Rubén Dario, Hernandez, Carlos Alberto, Csoszi, Tibor, De Vita, Ferdinando, Pfeiffer, Per, Sugimoto, Naotoshi, Kocsis, Judit, Csilla, Andràs, Bodoky, Gyorgy, Garnica Jaliffe, Georgina, Protsenko, Svetlana, Madi, Ayman, Wojcik, Elzbieta, Brenner, Baruch, Folprecht, Gunnar, Sarosiek, Tomasz, Peltola, Katriina Johanna, Bono, Peter, Ayala, Hubert, Aprile, Giuseppe, Gerardo, Cardellino Giovanni, Huitzil Melendez, Fidel David, Falcone, Alfredo, Di Costanzo, Francesco, Tehfe, Moustapha, Mineur, Laurent, García Alfonso, Pilar, Obermannova, Radka, Senellart, Hélène, Petty, Russell, Samuel, Leslie, Acs, Peter Istvan, Hussein, Maen Abdelkarim, Nechaeva, Marina N., Erdkamp, F.L.G., Won, Elizabeth, Bendell, Johanna Chock, Gallego Plazas, Javier, Lorenzen, Sylvie, Melichar, Bohuslav, Escudero, Miguel Angel, Pezet, Denis, Phelip, Jean-Marc, Kaen, Diego Lucas, Reeves, James A. Jr, Longo Muñoz, Federico, Madhusudan, Srinivasan, Barone, Carlo, Fein, Luis Enrique, Gomez Villanueva, Angel, Hebbar, Mohamed, Prausova, Jana, Visa Turmo, Laura, Vidal Barrull, Joana, Yilmaz, Mette Karen Nytoft, Beny, Alex, Van Laarhoven, H.M.W., DiCarlo, Brian Anthony, Esaki, Taito, Fujitani, Kazumasa, Geboes, Karen, Geva, Ravit, Kadowaki, Shigenori, Leong, Stephen, Machida, Nozomu, Raj, Moses Sundar, Ramirez Godinez, Francisco Javier, Ruzsa, Agnes, Ford, Hugo, Lawler, William E., Maisey, Nicolas Robert, Petera, Jiri, Shacham-Shmueli, Einat, Sinapi, Isabelle, Yamaguchi, Kensei, Hara, Hiroki, Beck, Joseph Thaddeus, Błasińska-Morawiec, Maria, Villalobos Valencia, Ricardo, Alcindor, Thierry, Bajaj, Madhuri, Berry, Scott, Gomez, Christina Maria, Dammrich, Daniel, Patel, Ravindranath, Taieb, Julien, Ten Tije, A.J., Burkes, Ronald L., Cabanillas, Fernando, Firdaus, Irfan, Chua, Cynthia Coo, Hironaka, Shuichi, Hofheinz, Ralf-Dieter, Lim, Howard J., Nordsmark, Marianne, Piko, Bela, Verma, Udit, Wadsley, Jonathan, Yukisawa, Seigo, Gutiérrez Delgado, Francisco, Denlinger, Crystal S., Kallio, Raija, Pikiel, Joanna, Wojcik-Tomaszewska, Joanna, Brezden-Masley, Christine, Jang, Raymond Woo-Jun, Pribylova, Jana, Sakai, Daisuke, Bartoli, Maria Alejandra, Cats, A., Grootscholten, M.I., Dichmann, Robert Andrew, Hool, Hugo, Shaib, Walid, Tsuji, Akihito, Van den Eynde, Marc, Velez-Cortez, Hector, Asmis, Timothy R., Fuchs, Charles S, Shitara, Kohei, Di Bartolomeo, Maria, Lonardi, Sara, Al-Batran, Salah-Eddin, Van Cutsem, Eric, Ilson, David H, Alsina, Maria, Chau, Ian, Lacy, Jill, Ducreux, Michel, Mendez, Guillermo Ariel, Alavez, Alejandro Molina, Takahari, Daisuke, Mansoor, Wasat, Enzinger, Peter C, Gorbounova, Vera, Wainberg, Zev A, Hegewisch-Becker, Susanna, Ferry, David, Lin, Ji, Carlesi, Roberto, Das, Mayukh, and Shah, Manish A

Published
2019
Full Text
View/download PDF

5. Navigating HER2-Low Testing in Invasive Breast Cancer: Update Recommendations for Pathologists.

Author

Bornstein-Quevedo, Leticia, de Anda-González, Jazmín, Lara-Torres, Cesar Octavio, Flores-Gutiérrez, Juan Pablo, Dorantes-Heredia, Rita, Bautista-Piña, Verónica, Zaragoza-Vargas, Perla, Alcaraz-Wong, Aldo, Soto-Sañudo, Ana Karen, Mendoza-Ramírez, Saulo, Salamanca-García, Moisés, Loyola-Rodríguez, Georgina, Gómez-Macías, Gabriela Sofia, Murguia-Perez, Mario, De Luna-Sánchez, Marcela, Villalobos-Valencia, Ricardo, Talamantes, Enrique, and Arce-Salinas, Claudia

Subjects
BREAST cancer, CANCER invasiveness, PATHOLOGISTS, INDIVIDUALIZED medicine, TUMOR markers
Abstract

The article discusses the importance of accurately distinguishing HER2-low from HER2-negative breast cancer, as novel ADCs have demonstrated activity in a large population of patients with HER2-low-expressing BC. While current guidelines recommend a dichotomous classification of HER2 as either positive or negative, the emergence of the HER2-low concept calls for standardization of HER2 testing in breast cancer, using currently available assays to better discriminate HER2 levels. This review covers the evolution and latest updates of the ASCO/CAP guidelines relevant to this important biomarker in breast cancer, including still-evolving concepts such as HER2 low, HER2 heterogeneity, and HER2 evolution. Our group presents the latest Mexican recommendations for HER2 status evaluation in breast cancer, considering the ASCO/CAP guidelines and introducing the HER2-low concept. In the era of personalized medicine, accurate HER2 status assessment remains one of the most important biomarkers in breast cancer, and the commitment of Mexican pathologists to theragnostic biomarker quality is crucial for providing the most efficient care in oncology. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Guía de práctica clínica para el manejo del cáncer de mama en estadios tempranos, localmente avanzados y metastásicos

Author

Carbajal-Saldaña, Brenda, primary, Maffuz-Aziz, Antonio, additional, Guadarrama-Orozco, Jorge Alberto, additional, Mayorga-Butrón, José Luis, additional, Quintero-Beuló, Gregorio, additional, García-Tinoco, María de la Luz, additional, Rivera, Samuel, additional, Ochoa-Carrillo, Francisco Javier, additional, Bargalló-Rocha, Juan Enrique, additional, Maldonado-Magos, Federico, additional, Hernández-Montes de Oca, Raymundo, additional, Villegas-Carlos, Felipe, additional, Herrera, Marytere, additional, Romero-Robles, Luis Alfonso, additional, Deneken-Hernández, Zuratzi, additional, Rivera-Sánchez, Daniel, additional, Arce-Salinas, Claudia Haydeé, additional, Grajales-Álvarez, Rocío Crystal, additional, García-Orozco, Nathaly, additional, Villalobos-Valencia, Ricardo, additional, Lozano-Ruiz, Francisco Javier, additional, Hernández-Hernández, Betsabé, additional, Tenorio-Torres, Juan Alberto, additional, Domínguez-Reyes, Carlos Alberto, additional, Pluma-Jiménez, Miguel Ángel, additional, Chavarri-Guerra, Yanin, additional, Ramos-Prudencio, Rubí, additional, Villarreal-Garza, Cynthia Mayté, additional, Blake-Cerda, Mónica, additional, Flores-Vázquez, Fabiola, additional, Garnica-Jaliffe, Georgina, additional, Magallanes-Maciel, Manuel Ernesto, additional, Bautista-Aragón, Yolanda, additional, Reséndiz Colosia, Jaime Alonso, additional, Velasco Hidalgo, Liliana, additional, Zapata-Tarrés, Marta, additional, Aguilar Ortíz, Marco Rodrigo, additional, Maza Ramos, Gibert, additional, Montaño Velázquez, Bertha Beatriz, additional, Figueroa-Morales, Marco Antonio, additional, and González-Garay, Alejandro, additional

Published
2022
Full Text
View/download PDF

8. Resources for the attention of patients with breast cancer in Mexico

Author

Bargalló-Rocha, Enrique, primary, Ruvalcaba-Limón, Eva, additional, Quintero-Beuló, Gregorio, additional, Reséndiz Colosia, Jaime Alonso, additional, Salas González, Efraín, additional, Serrano-Olvera, Juan Alberto, additional, Silva-Juan, Alejandro, additional, Maffuz-Aziz, Antonio, additional, Figueroa-Martínez, Pedro, additional, Villalobos-Valencia, Ricardo, additional, Villarreal-Garza, Cynthia Mayté, additional, Cardona-Huerta, Servando, additional, Serrano-Ortiz, Rodrigo, additional, Rodríguez-Trejo, Amelia, additional, Barragán-Curiel, Adolfo Eduardo, additional, and Rodríguez-Cuevas, Sergio, additional

Published
2022
Full Text
View/download PDF

9. Cuarto Consenso Nacional de Cáncer de Ovario

Author

Gallardo-Rincón, Dolores, primary, Ruvalcaba-Limón, Eva, additional, Silva-García, Araceli, additional, Aranda-Flores, Carlos Eduardo, additional, Quijano-Castro, Odilón Félix, additional, Bañuelos-Flores, Joel, additional, Montalvo-Esquivel, Gonzalo, additional, Pérez-Quintanilla, Milagros Clementina, additional, Bahena-González, Antonio, additional, Alamilla-García, Gabriela, additional, Espinosa-Romero, Raquel, additional, Álvarez-Gómez, Rosa María, additional, Carrillo-Garibaldi, Óscar Joel, additional, Cantú de León, David, additional, Herbert-Núñez, Guillermo, additional, Hinojosa-García, Luz María, additional, Morales-Palomares, Miguel Ángel, additional, Ochoa-Carrillo, Francisco Javier, additional, Oñate-Ocaña, Luis Fernando, additional, Oliva-Posada, Juan C., additional, Salcedo-Hernández, Rosa María, additional, Maffuz-Aziz, Antonio, additional, Isla-Ortiz, David, additional, Medina-Castro, Juan Manuel, additional, Güemes-Meza, Agustín, additional, Rodríguez-Trejo, Amelia, additional, Ávila-Monteverde, Enrique, additional, Tabarez-Ortiz, Adán, additional, Salcedo-Hernández, Rosa Angélica, additional, del Real-Ordóñez, Sarish, additional, Garnica-Jaliffe, Georgina, additional, Hernández-Luis, Gisela, additional, Morán-Mendoza, Andrés, additional, Rivera, Samuel, additional, Cortés-Esteban, Patricia, additional, Villalobos-Valencia, Ricardo, additional, Enríquez-Aceves, Isabel, additional, Green-Renner, Dan, additional, Morales-Vásquez, Flavia, additional, Durazo-Bustamante, Fernando, additional, Ruiz-García, Erika, additional, Álvarez- Avitia, Miguel Ángel, additional, and Gómez-García, Eva María, additional

Published
2022
Full Text
View/download PDF

10. Recomendaciones sobre el tratamiento farmacológico del cáncer de ovario epitelial en México

Author

Gallardo-Rincón, Dolores, primary, Bahena-González, Antonio, additional, Álvarez, Rosa M., additional, Gómez-García, Eva M., additional, Cortés-Esteban, Patricia, additional, Villalobos-Valencia, Ricardo, additional, Hernández-Hernández, Carlos A., additional, Morán-Mendoza, Andrés de J., additional, Salcedo-Hernández, Rosa A., additional, and Cetina-Pérez, Lucely del C., additional

Published
2021
Full Text
View/download PDF

12. ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer

Author

Galicia-Carmona, Tatiana, primary, Arango-Bravo, Eder, additional, Serrano-Olvera, Juan a, additional, Flores-de La Torre, Celia, additional, Cruz-Esquivel, Ivan, additional, Villalobos-Valencia, Ricardo, additional, Morán-Mendoza, Andrés, additional, Castro-Eguiluz, Denisse, additional, and Cetina-Pérez, Lucely, additional

Published
2021
Full Text
View/download PDF

13. Recursos para la atención de pacientes con cáncer de mama en México

Author

Bargalló-Rocha, Enrique, primary, Ruvalcaba-Limón, Eva, additional, Quintero-Beuló, Gregorio, additional, Reséndiz Colosia, Jaime Alonso, additional, Salas González, Efraín, additional, Serrano-Olvera, Juan Alberto, additional, Silva-Juan, Alejandro, additional, Maffuz-Aziz, Antonio, additional, Figueroa-Martínez, Pedro, additional, Villalobos-Valencia, Ricardo, additional, Villarreal-Garza, Cynthia Mayté, additional, Cardona-Huerta, Servando, additional, Serrano-Ortiz, Rodrigo, additional, Rodríguez-Trejo, Amelia, additional, Barragán-Curiel, Adolfo Eduardo, additional, and Rodríguez-Cuevas, Sergio, additional

Published
2019
Full Text
View/download PDF

14. Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.

Author

Penson, Richard T., primary, Villalobos Valencia, Ricardo, additional, Cibula, David, additional, Colombo, Nicoletta, additional, Leath, Charles A., additional, Bidziński, Mariusz, additional, Kim, Jae-Weon, additional, Nam, Joo-Hyun, additional, Madry, Radoslaw, additional, Hernández, Carlos Hernández, additional, Mora, Paulo Alexandre Ribeiro, additional, Ryu, Sang Young, additional, Milenkova, Tsveta, additional, Lowe, Elizabeth S., additional, Barker, Laura, additional, and Scambia, Giovanni, additional

Published
2019
Full Text
View/download PDF

15. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Fuchs, Charles S, primary, Shitara, Kohei, additional, Di Bartolomeo, Maria, additional, Lonardi, Sara, additional, Al-Batran, Salah-Eddin, additional, Van Cutsem, Eric, additional, Ilson, David H, additional, Alsina, Maria, additional, Chau, Ian, additional, Lacy, Jill, additional, Ducreux, Michel, additional, Mendez, Guillermo Ariel, additional, Alavez, Alejandro Molina, additional, Takahari, Daisuke, additional, Mansoor, Wasat, additional, Enzinger, Peter C, additional, Gorbounova, Vera, additional, Wainberg, Zev A, additional, Hegewisch-Becker, Susanna, additional, Ferry, David, additional, Lin, Ji, additional, Carlesi, Roberto, additional, Das, Mayukh, additional, Shah, Manish A, additional, Luft, Alexander V., additional, Karaseva, Nina A., additional, Kowalyszyn, Rubén Dario, additional, Hernandez, Carlos Alberto, additional, Csoszi, Tibor, additional, De Vita, Ferdinando, additional, Pfeiffer, Per, additional, Sugimoto, Naotoshi, additional, Kocsis, Judit, additional, Csilla, Andràs, additional, Bodoky, Gyorgy, additional, Garnica Jaliffe, Georgina, additional, Protsenko, Svetlana, additional, Madi, Ayman, additional, Wojcik, Elzbieta, additional, Brenner, Baruch, additional, Folprecht, Gunnar, additional, Sarosiek, Tomasz, additional, Peltola, Katriina Johanna, additional, Bono, Peter, additional, Ayala, Hubert, additional, Aprile, Giuseppe, additional, Gerardo, Cardellino Giovanni, additional, Huitzil Melendez, Fidel David, additional, Falcone, Alfredo, additional, Di Costanzo, Francesco, additional, Tehfe, Moustapha, additional, Mineur, Laurent, additional, García Alfonso, Pilar, additional, Obermannova, Radka, additional, Senellart, Hélène, additional, Petty, Russell, additional, Samuel, Leslie, additional, Acs, Peter Istvan, additional, Hussein, Maen Abdelkarim, additional, Nechaeva, Marina N., additional, Erdkamp, F.L.G., additional, Won, Elizabeth, additional, Bendell, Johanna Chock, additional, Gallego Plazas, Javier, additional, Lorenzen, Sylvie, additional, Melichar, Bohuslav, additional, Escudero, Miguel Angel, additional, Pezet, Denis, additional, Phelip, Jean-Marc, additional, Kaen, Diego Lucas, additional, Reeves, James A. Jr, additional, Longo Muñoz, Federico, additional, Madhusudan, Srinivasan, additional, Barone, Carlo, additional, Fein, Luis Enrique, additional, Gomez Villanueva, Angel, additional, Hebbar, Mohamed, additional, Prausova, Jana, additional, Visa Turmo, Laura, additional, Vidal Barrull, Joana, additional, Yilmaz, Mette Karen Nytoft, additional, Beny, Alex, additional, Van Laarhoven, H.M.W., additional, DiCarlo, Brian Anthony, additional, Esaki, Taito, additional, Fujitani, Kazumasa, additional, Geboes, Karen, additional, Geva, Ravit, additional, Kadowaki, Shigenori, additional, Leong, Stephen, additional, Machida, Nozomu, additional, Raj, Moses Sundar, additional, Ramirez Godinez, Francisco Javier, additional, Ruzsa, Agnes, additional, Ford, Hugo, additional, Lawler, William E., additional, Maisey, Nicolas Robert, additional, Petera, Jiri, additional, Shacham-Shmueli, Einat, additional, Sinapi, Isabelle, additional, Yamaguchi, Kensei, additional, Hara, Hiroki, additional, Beck, Joseph Thaddeus, additional, Błasińska-Morawiec, Maria, additional, Villalobos Valencia, Ricardo, additional, Alcindor, Thierry, additional, Bajaj, Madhuri, additional, Berry, Scott, additional, Gomez, Christina Maria, additional, Dammrich, Daniel, additional, Patel, Ravindranath, additional, Taieb, Julien, additional, Ten Tije, A.J., additional, Burkes, Ronald L., additional, Cabanillas, Fernando, additional, Firdaus, Irfan, additional, Chua, Cynthia Coo, additional, Hironaka, Shuichi, additional, Hofheinz, Ralf-Dieter, additional, Lim, Howard J., additional, Nordsmark, Marianne, additional, Piko, Bela, additional, Verma, Udit, additional, Wadsley, Jonathan, additional, Yukisawa, Seigo, additional, Gutiérrez Delgado, Francisco, additional, Denlinger, Crystal S., additional, Kallio, Raija, additional, Pikiel, Joanna, additional, Wojcik-Tomaszewska, Joanna, additional, Brezden-Masley, Christine, additional, Jang, Raymond Woo-Jun, additional, Pribylova, Jana, additional, Sakai, Daisuke, additional, Bartoli, Maria Alejandra, additional, Cats, A., additional, Grootscholten, M.I., additional, Dichmann, Robert Andrew, additional, Hool, Hugo, additional, Shaib, Walid, additional, Tsuji, Akihito, additional, Van den Eynde, Marc, additional, Velez-Cortez, Hector, additional, and Asmis, Timothy R., additional

Published
2019
Full Text
View/download PDF

16. Cancer pain management: recommendations from a Latin-American experts panel

Author

Escobar Alvarez, Yolanda, primary, Agamez Insignares, Claudia, additional, Ahumada Olea, Monica, additional, Barajas, Olga, additional, Calderillo, German, additional, Calvache Guamán, Jenny Cecilia, additional, Caponero, Ricardo, additional, Cavenago Salazar, Benjamín A, additional, Del Giglio, Auro, additional, Pupo Araya, Ana Rocío, additional, Villalobos-Valencia, Ricardo, additional, Yepes Pérez, Andrés, additional, and Zumelzu Delgado, Nilda, additional

Published
2017
Full Text
View/download PDF

17. Final results from a phase III trial evaluating panitumumab (pmab) + best supportive care (BSC) vs BSC in chemorefractory wild-type (WT) KRAS exon 2 and WT RAS metastatic colorectal cancer (mCRC).

Author

Kim, Tae Won, primary, Elme, Anneli, additional, Kusic, Zvonko, additional, Park, Joon Oh, additional, Udrea, Anghel Adrian, additional, Kim, Sun Young, additional, Ahn, Joong Bae, additional, Villalobos Valencia, Ricardo, additional, Srinivasan, Krishnan, additional, Bilic, Ante, additional, Manojlovic, Nebojsa, additional, Dong, Jun, additional, Guan, Xuesong, additional, Lofton-Day, Catherine, additional, Jung, A. Scott, additional, and Vrdoljak, Eduard, additional

Published
2016
Full Text
View/download PDF

18. An open label, randomized phase III trial evaluating the treatment (tx) effects of panitumumab (pmab) + best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC.

Author

Kim, Tae Won, primary, Elme, Anneli, additional, Kusic, Zvonko, additional, Park, Joon Oh, additional, Udrea, Anghel Adrian, additional, Kim, Sun Young, additional, Ahn, Joong Bae, additional, Villalobos Valencia, Ricardo, additional, Srinivasan, Krishnan, additional, Bilic, Ante, additional, Manojlovic, Nebojsa, additional, Dong, Jun, additional, Guan, Xuesong, additional, Lofton-Day, Catherine, additional, Jung, A. Scott, additional, and Vrdoljak, Eduard, additional

Published
2016
Full Text
View/download PDF

19. Use of Bevacizumab in Metastatic Colorectal Cancer

Author

Zinser-Sierra, Juan W., Rodríguez-Ramírez, Saúl, Villalobos-Valencia, Ricardo, and Ramírez-Márquez, Marcelino

Subjects
Bevacizumab, Pharmacology, Clinical Trials as Topic, Humans, Angiogenesis Inhibitors, Review Article, Neoplasm Metastasis, Antibodies, Monoclonal, Humanized, Colorectal Neoplasms, digestive system diseases, Biomarkers
Abstract

Colorectal cancer is one of the most common cancers worldwide, and although associated mortality rates in South American countries are generally among the lowest in the world, they are on the rise. The prognosis of patients diagnosed with metastatic colorectal cancer has improved markedly over the last 12 years, increasing from 5 months with best supportive care to almost 2 years with combination chemotherapy plus bevacizumab. New prognostic and predictive biomarkers have been identified to guide therapy. Prognostic markers indicate patient survival independent of therapy and include disease stage, mutational status, and carcinoembryonic antigen. More recently, predictive markers of treatment outcomes have been identified. The most studied are mutations of the KRAS and BRAF genes, which are associated with resistance to epidermal growth factor receptor-targeted therapy. Tumor blood vessels have a number of structural and functional abnormalities that result in increased tumor vascularity and growth driven by angiogenesis. The anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab, which binds to and neutralizes VEGF-A, has become a central part of the treatment of metastatic colorectal cancer. The addition of bevacizumab to fluorouracil (5-FU)/leucovorin, irinotecan plus bolus 5-FU/leucovorin, or irinotecan plus infusional 5-FU/leucovorin significantly improves the overall survival of patients with previously untreated metastatic colorectal cancer. In addition, a significant increase in overall survival is seen when bevacizumab is added to oxaliplatin plus infusional 5-FU/leucovorin (FOLFOX) in patients with metastatic colorectal cancer who progressed on a non-bevacizumab-containing regimen. Although the majority of studies were performed prior to the identification of KRAS and BRAF as predictive biomarkers, subsequent analysis has shown the benefits of bevacizumab occur independently of the mutational status of these genes. In patients who have progressed on a bevacizumab-containing regimen, continuation of bevacizumab is significantly associated with an improved survival based on observational cohort studies. Surgical resection is recommended in patients with metastatic colorectal cancer where complete removal of tumors can be achieved. Perioperative chemotherapy using FOLFOX for 3 months before and 3 months after surgery is associated with a 9% improvement in 3-year survival. The use of chemotherapy in patients initially deemed unresectable has produced resection rates approaching 40%, and the addition of bevacizumab to chemotherapy in this setting is feasible, safe, and effective. In a study of 219 patients, the addition of bevacizumab to FOLFOX was associated with a significant increase in major or complete pathologic response compared with FOLFOX alone. Improvements in patient survival have changed the treatment paradigm for metastatic colorectal cancer. Newer approaches view treatment not as distinct lines of therapy but as a continuum that includes personalized treatment plans offering maintenance therapy and even drug holidays between aggressive treatment periods. This approach achieves similar efficacy outcomes with reduced toxicity, and investigation of the role of bevacizumab as maintenance therapy is ongoing.

Full Text
View/download PDF

20. Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.

Author

Scambia G, Villalobos Valencia R, Colombo N, Cibula D, Leath CA 3rd, Bidziński M, Kim JW, Nam JH, Madry R, Hernández C, Mora PAR, Ryu SY, Ah-See ML, Lowe ES, Lukashchuk N, Carter D, and Penson RT

Abstract

Olaparib treatment significantly improved objective response rate (primary end point) and progression-free survival versus nonplatinum chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer in the open-label phase III SOLO3 trial (ClinicalTrials.gov identifier: NCT02282020). We report final overall survival (OS; prespecified secondary end point), post hoc OS analysis by number of previous chemotherapy lines, and exploratory BRCA reversion mutation analysis. Two hundred sixty-six patients were randomly assigned 2:1 to olaparib tablets (300 mg twice daily; n = 178) or physician's choice of single-agent nonplatinum chemotherapy (pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topotecan; n = 88). OS was similar with olaparib versus chemotherapy (hazard ratio [HR], 1.07 [95% CI, 0.76 to 1.49]; P = .71, median 34.9 and 32.9 months, respectively, full analysis set). OS with olaparib was favorable in patients with two previous chemotherapy lines (HR, 0.83 [olaparib v chemotherapy] [95% CI, 0.51 to 1.38]; median 37.9 v 28.8 months); however, a potential detrimental effect was seen in patients with at least three previous chemotherapy lines (HR, 1.33 [95% CI, 0.84 to 2.18]; median 29.9 v 39.4 months). BRCA reversion mutations might have contributed to this finding. No patient randomly assigned to olaparib with a BRCA reversion mutation detected at baseline (6 of 170 [3.5%]) achieved an objective tumor response.

Published
2024
Full Text
View/download PDF

21. Addressing the unmet needs of women with breast cancer in Mexico: a non-randomised pilot study of the digital ePRO intervention.

Author

Contreras Sánchez SE, Doubova SV, Martinez Vega IP, Grajales Álvarez R, Villalobos Valencia R, Dip Borunda AK, Lio Mondragón L, Martínez Pineda WJ, Nuñez Cerrillo JG, Huerta López AD, Zalapa Velázquez R, Mendoza Ortiz V, Vázquez Zamora VJ, Montiel Jarquín ÁJ, García Galicia A, Talamantes Gómez EI, Sánchez Reyes R, Aguirre Gómez J, Ayala Anzures ME, Zapata Tarrés M, Monroy A, and Leslie HH

Subjects
Humans, Female, Pilot Projects, Middle Aged, Mexico, Adult, Aged, Young Adult, Internet-Based Intervention, Feasibility Studies, Breast Neoplasms therapy, Quality of Life, Patient Reported Outcome Measures
Abstract

Objectives: This study aimed to explore the acceptability, feasibility, usability, and preliminary effect of an electronic patient-reported outcome (ePRO) intervention for patients with breast cancer in Mexico., Design: We conducted a multimethod non-randomised pilot study. We used a pre-test/post-test design for quantitative assessment of the intervention's effect on patients' supportive care needs and quality of life. We conducted in-depth interviews (IDIs) with participants and healthcare workers to explore the intervention's benefits and barriers and understand its feasibility., Participants: 50 women aged 20-75 diagnosed with stage I-III breast cancer were enrolled within 2 weeks of starting neoadjuvant or adjuvant treatment with chemotherapy or radiotherapy. We excluded illiterate women and those with visual impairment, cognitive disability or severe depression. IDIs were conducted with 18 participants and 10 healthcare providers., Setting: Oncology services in three public hospitals of the Mexican Social Security Institute., Intervention: The ePRO intervention consisted of a responsive web application for weekly symptom reporting combined with proactive follow-up by nurses guided by predefined clinical algorithms for 6 weeks., Results: 50 women were enrolled out of 66 eligible patients approached (75.8%). All 50 completed the 4-week follow-up assessment (100% retention). Completion of the symptom registry declined from 100% in week 1 to 66% in week 6. Participants experienced decreases in supportive care needs and increased quality of life. The ePRO application was rated highly usable. Participants and health professionals both perceived intervention benefits. Drawbacks included poor fit for women receiving radiotherapy and challenges using the application for women with low digital literacy or experiencing severe symptoms., Conclusions: This pilot study provided evidence of the high usability and potential efficacy of a web-based ePRO intervention. We revised recruitment during the pilot to include multiple facilities, and we will further revise for the randomised trial to address barriers to successful ePRO implementation., Trial Registration Number: ClinicalTrials.gov ID: NCT05925257., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2024
Full Text
View/download PDF

22. Recommendations on the pharmacological treatment of epithelial ovarian cancer in Mexico.

Author

Gallardo-Rincón D, Bahena-González A, Álvarez RM, Gómez-García EM, Cortés-Esteban P, Villalobos-Valencia R, Hernández-Hernández CA, Morán-Mendoza AJ, Salcedo-Hernández RA, and Cetina-Pérez LDC

Subjects
Carcinoma, Ovarian Epithelial drug therapy, Humans, Mexico epidemiology, Ovarian Neoplasms drug therapy, Ovarian Neoplasms epidemiology
Abstract

Ovarian cancer is the third most frequent gynaecological malignancy worldwide and in Mexico, with a high mortality rate, due to that in many cases its diagnosis is made in advanced stages. Prognosis is important for determining the subtype and the degree of evolution. During lasts years, the management of ovarian cancer has undergone an important evolution with the incorporation of new therapeutic options, which in turn represent an increase in the survival of these patients. We present recommendations for the management of ovarian cancer developed by an expert panel Mexican based on available evidence so far and the characteristics of health care in the country., (Copyright: © 2021 Permanyer.)

Published
2021
Full Text
View/download PDF

23. [Concomitant treatment with gemcitabine and radiotherapy in patients with advanced stages of epidermoid carcinoma originating in the head and neck. A phase II sutdy].

Author

Bustamante-Valles Fde T, Calva-Espinosa AL, Gallegos-Hernández JF, Villalobos-Valencia R, Castruita AL, Silva JA, and Flores-Díaz R

Subjects
Adult, Aged, Carcinoma, Squamous Cell pathology, Combined Modality Therapy, Deoxycytidine therapeutic use, Female, Head and Neck Neoplasms pathology, Humans, Male, Middle Aged, Neoplasm Staging, Prospective Studies, Gemcitabine, Antimetabolites, Antineoplastic therapeutic use, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell radiotherapy, Deoxycytidine analogs & derivatives, Head and Neck Neoplasms etiology, Head and Neck Neoplasms radiotherapy
Abstract

Background: Surgery, radiotherapy or radiotherapy alone (RTA) constitute conventional treatment regimes for advanced stages of squamous cell carcinoma originating in the head and neck mucosa. Nevertheless, the results in advanced regional carcinoma (ARC) are disappointing. The chemotherapy-radiotherapy (CHT-RT) association has shown to be superior to RTA in irresectable disease and in resectable disease it could substitute initial surgery as a rescue alternative., Objective: Our objective is to report the response rate and toxicity of concurrent treatment with Gemcitabine and Radiotherapy (GRT) in patients with ARC. In a prospective design, patients with ARC received concurrent GRT; the global, complete and partial response rate as well as toxicity were assessed., Material and Methods: 15 patients were included, 5 women and 10 men, 73% in stage IVa; 13/15 showed a global response (87%), a complete response was observed in 9 cases (60%) (RC) and 2 showed progress., Results: All patients included showed toxicity, the most frequent one was level 4 mucositis in 46%, of this 40% required nutritional support by catheter or gastrostomy. One patient in RC died due to sepsis. None of them suspended treatment., Conclusion: The GRT association offers a complete response rate of 60%; nevertheless morbidity was not insignificant; randomized studies with a larger number of patients will be required to allow us to outline the optimal therapeutic scheme.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results